Posted by Michael Wonder on 21 Nov 2023
Anavex initiates regulatory submission of oral blarcamesine for Alzheimer’s disease to EMA
20 November 2023 - Anavex Life Sciences announced today that representatives of Anavex met with team members of the EMA.
These meetings discussed the debilitating pathology of Alzheimer’s disease and Anavex’s blarcamesine (ANAVEX 2-73) Alzheimer’s disease clinical program results, including data obtained in the ANAVEX 2-73-AD-004 study.
